Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis.

Conclusions: IVGC, alone or combination with OR, and teprotumumab should be preferred as the most effective strategies for active moderate to severe TED. Teprotumumab showed profound effect on proptosis reduction. OIGC, OR, and somatostatin analogs showed some statistical benefit and can be employed as second-line treatment strategies. RTX is a promising biologic agent, but more RCTs are required to define its appropriate role in treating TED. PMID: 30647961 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/30647961?dopt=Abstract

Source: Journal of Ophthalmology - January 18, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research